Linnea Fulton

<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist et al. · Clinical Cancer Research · 2016 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Matthew J. Niederst, Lecia V. Sequist, John T. Poirier et al. · Nature Communications · 2015 · 633 citations · Full text

Medicine, Cancer Biology, Oncology +17

Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

Zofia Piotrowska, Matthew J. Niederst, Chris Karlovich et al. · Cancer Discovery · 2015 · 460 citations · Full text

Medicine, Oncology, Pharmacology +16

A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs

David M. Vail, Henrik von Euler, A.W. Rusk et al. · Journal of Veterinary Internal Medicine · 2012 · 40 citations · Full text

Medicine, Oncology, Pharmacology +14

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib

Mizuki Nishino, Suzanne E. Dahlberg, Linnea Fulton et al. · Academic Radiology · 2016 · 34 citations

Medicine, Oncology, Pharmacology +14